Biofrontera Q1 2025 revenue $8.6M (+9% YoY); net loss narrows to $4.2M

Biofrontera Inc.

2025-Q1 EPS reported -$0.47 revenue$8,588,000

Total revenues $8.6M, +8.7% YoY; net loss $4.2M ($0.47 per share) vs $10.4M ($2.88) prior year.
Cash and equivalents $1.8M at March 31, 2025, down from $5.9M at Dec 31, 2024.
Phase 3 trial for Ameluz in actinic keratoses on extremities, neck and trunk enrolled final patient; Phase 3 sBCC study completed 1-year follow-up.
Phase 2b study for Ameluz in moderate to severe acne vulgaris completed patient enrollment.
Patent approval extended Ameluz protection to December 2043 for revised formulation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.